Transcranial magnetic stimulation of visual cortex in migraine patients: a systematic review with meta-analysis

Francesco Brigo · Monica Storti · Raffaele Nardone · Antonio Fiaschi · Luigi Giuseppe Bongiovanni · Frediano Tezzon · Paolo Manganotti

Abstract We systematically reviewed the literature to evaluate the prevalence of phosphenes and the phosphene threshold (PT) values obtained during single-pulse transcranial magnetic stimulation (TMS) in adults with migraine. Controlled studies measuring PT by single-pulse TMS in adults with migraine with or without aura (MA, MwA) were systematically searched. Prevalence of phosphenes and PT values were assessed calculating mean difference (MD) and odds ratio (OR) with 95 % confidence intervals (CI). Ten trials (277 migraine patients and 193 controls) were included. Patients with MA had statistically significant lower PT compared with controls when a circular coil was used (MD $-28.33; 95 \% \text{CI} -36.09 \text{ to } -20.58$); a similar result was found in MwA patients (MD $-17.12; 95 \% \text{CI} -23.81 \text{ to } -10.43$); using a figure-of-eight coil the difference was not statistically significant. There was a significantly higher phosphene prevalence in MA patients compared with control subjects (OR $4.21; 95 \% \text{CI}$ 1.18–15.01). No significant differences were found either in phosphene reporting between patients with MwA and controls, or in PT values obtained with a figure-of-eight coil in MA and MwA patients versus controls. Overall considered, these results support the hypothesis of a primary visual cortex hyper-excitability in MA, providing not enough evidence for MwA. A significant statistical heterogeneity reflects clinical and methodological differences across studies, and higher temporal variabilities among PT measurements over time, related to unstable excitability levels. Patients should therefore be evaluated in the true interictal period with an adequate headache-free interval. Furthermore, skull thickness and ovarian cycle should be assessed as possible confounding variables, and sham stimulation should be performed to reduce the rate of false positives. Phosphen prevalence alone cannot be considered a measure of cortical excitability, but should be integrated with PT evaluation.

Keywords Meta-analysis · Migraine · Phosphenes · Systematic review · Transcranial magnetic stimulation

Introduction

Several aspects in the pathophysiology of migraine are still unknown, although an altered cortical excitability has been proposed as an important factor predisposing to the spontaneous cortical spreading depression which is thought to represent the pathophysiological basis of the migraine with aura [1]. A generalized cortical inter-ictal hyper-excitability, more pronounced in the visual cortex, has been suggested in migraine [1, 2], although other psychophysical tests of the visual system yielded results suggestive of occipital cortex hypo-excitability or lack of intra-cortical...
excitability [3]. Neurophysiologic evidence for inter-ictal primary visual cortex hyper-excitability is nevertheless controversial, with some studies demonstrating amplitude differences of visual evoked responses in patients with migraine compared with controls [4–6], and other studies not confirming such results [7, 8]. However, a recent study using VEP with paired pulse stimulation in patients affected by migraine without aura demonstrated a reduced inhibitory response to the second pulse, compatible with a condition of reduced inhibition-increased excitability [9].

Transcranial magnetic stimulation (TMS) has been proposed as an innovative tool to noninvasively and directly assess the cortical physiology and excitability in vivo. In recent years, TMS has been repeatedly used in patients with migraine to test occipital cortex excitability by measuring phosphene threshold (PT), defined as the minimum intensity of a TMS pulse needed to evoke phosphenes: PT is inversely related to the overall level of visual cortex excitability [10], so that a low PT is considered expression of primary visual cortex hyper-excitability. Important discrepancies among different studies do, however, exist, with some groups reporting increased, and others decreased inter-ictal PT. These studies produced conflicting results also regarding prevalence of stimulation-induced phosphenes in migraineurs compared with healthy controls. These discrepancies make it very difficult to reach a definite conclusion by simple summation of previous results. We therefore decided to undertake a systematic review and a meta-analysis of studies evaluating phosphene prevalence and inter-ictal PT values during single-pulse TMS in adults.

Some reviews previously assessed this topic, but always in a narrative and subjective way, not using systematic and explicit methods to identify, select and critically appraise studies, and to extract data, and to analyse them with statistical methods [11–15]. The present review represents therefore the first attempt to appraise the available literature on magneto-phosphenes in migraine with systematic methods.

Methods

This review was guided by a written pre-specified protocol describing research questions, review methods, plan for data extraction and synthesis.

Our aim was to critically and systematically evaluate the literature to determine (A) the prevalence of phosphenes and (B) the PT values obtained during single-pulse TMS in adults with migraine compared with controls.

We therefore included only controlled studies measuring PT by single-pulse TMS in adults of either gender with migraine (with or without aura; defined according to International Headache Society criteria, 1988 and 2004 [16, 17]) and in control subjects, regardless of stimulator characteristics such as coils’ shape, size and maximum magnetic field strength. Uncontrolled studies, studies conducted in children or performing TMS with paired magnetic stimuli, or stimulating cortical regions other than primary visual cortex were excluded. Children were excluded in order to exclude an excessively high clinical heterogeneity (related to age differences) and methodological heterogeneity (e.g. related to the use of smaller TMS coils, or with lower stimulation intensity in this population). Studies performing TMS with paired magnetic stimuli were excluded to prevent a high heterogeneity due to the use of two different methods. Also consecutive TMS studies were excluded.

The MEDLINE (accessed by Pubmed; 1966–June 2011) and EMBASE (1988–June 2011) electronic databases were searched using the following medical subject headings (MeSH): “Phosphenes”, “Transcranial Magnetic Stimulation” and “Migraine Disorders”, as well as following free terms, combined in multiple search strategies with Boolean operators (see “Appendix”) in order to find relevant articles: “migrain*”, “phosphene*”, “phosphen*”, “phosphene threshold”. Furthermore, all references lists in identified trials were scrutinized for studies not indexed in the electronic databases. In order to provide a transparency of results as great as possible, and to allow readers to reproduce the methodology we adopted, and considering that in abstracts many methodological aspects are not declared and results are often synthesized, only in extenso papers and articles already published were considered eligible for inclusion.

Following data were extracted: inclusion/exclusion criteria, number and sex of participants, headache-free interval, menstrual phase, stimulator characteristics, blinding, definition of PT, and inter-stimulus interval. Data were independently extracted by two review authors (FB, MS) and cross-checked. All disagreements were resolved by consensus. Although we did not systematically evaluate the inter-rater agreement for the data extraction, consensus reached through discussion ensured unanimous decisions.

In case of missing or incomplete data, principal investigators of included trials were contacted and additional information requested.

Two review authors (FB, MS) independently assessed the methodological quality of each study and risk of bias, focusing on blinding and other potential sources of bias. Provided we thought it clinically appropriate, and no important clinical and methodological heterogeneity was found, we summarized results in a meta-analysis.

In order to minimize methodological heterogeneity between studies evaluating PT values, we separately analyzed results from studies using a circular and a figure-of-eight coil; moreover, to reduce clinical heterogeneity, in
each outcome (phosphen prevalence; PT values), we separately analyzed data on migraine with aura from data on migraine without aura.

Phosphen reporting after TMS procedure (dichotomous data) was analyzed by calculating odds ratio (OR) for each study, with the uncertainty in each trial being expressed using 95% confidence intervals (CI).

PT values (continuous data) were analyzed by calculating the mean difference for each trial, with the uncertainty in each study being expressed using 95% CI. For PT values, total of events in each group was the number of participants reporting phosphenes. A weighted effect across studies was also calculated. In the evaluation of PT, we planned also to perform an individual patient data meta-analysis including subjects not reporting phosphenes as bearing a 100% threshold.

Homogeneity among study results was evaluated using a standard Chi squared test, combined with the I² statistics, and the hypothesis of homogeneity was rejected if the p value was less than 0.10. The interpretation of I² for heterogeneity was made as follows: 0–25% represents low heterogeneity, 25–50% moderate heterogeneity, 50–75% substantial heterogeneity, 75–100% high heterogeneity [18]. Phosphen prevalence and PT values were combined to obtain a summary estimate of value (and the corresponding CI) using a random-effect model. Random-effects model is considered more conservative than a fixed-effect model, since it takes into account the variability between studies, thus leading to wider CIs.

Statistical analyses were undertaken with the Review Manager software developed by the Cochrane Collaboration (5.1).

Results

Description of included studies (Table 1)

The search strategy described above yielded 113 results (78 MEDLINE, 31 EMBASE, 3 in reference lists, 1 unpublished study).

Twenty studies were provisionally selected. We excluded ten studies after reading the full published articles: one study was excluded because paired magnetic stimuli were used to induce phosphenes [19]; in one study TMS was applied laterally over visual area V5, and not over primary visual cortex [20]; two studies used a consecutive TMS procedure [21, 22]. One study, conducted on patients with episodic migraine and on patients with ‘probable chronic migraine’, was provisionally included in this review [23], but later excluded because of the lack of further information on migraine features (e.g. presence of aura), and in order to avoid an excessively high clinical heterogeneity among studies. One unpublished study [24] and four studies published as abstracts [25–28].

Thus 10 trials, comprising 277 migraine patients and 193 control subjects, contributed to this review [29–38]: the earliest was published in 1998 and the most recent in 2006. Five studies were conducted by two different groups with common authors (three by Aurora [29–31], two by Bohoyin [32, 33]). One study performing repetitive TMS was included in the review because PT was identified using single-pulse TMS [32].

More detailed characteristics of included studies are reported in Table 1.

Risk of bias in included studies

Five studies were conducted by groups with common authors and published within a few years apart [29–33], so that the probability of overlapping cases and/or controls could not be ruled out, also because, although contacted, authors did not clarify such an aspect. Thus, it was impossible to determine whether some included papers represent duplicate publications of one study or two separate studies (multiple publication bias). The inclusion of duplicated data may therefore have lead to overestimation of results from these studies.

Two studies reported that the investigator was blinded to the diagnostic subtype of migraine [33, 34]. In two studies, the investigators were reported as blinded to the diagnoses [31, 35], so that it was possible that they knew which participants were controls and which were migraineurs. In one study, the investigators were not blinded regarding headache status [36]. In four studies, the subjects were not informed of what to expect, but were asked to report all sensations they experienced [29–31, 34]; in six studies, the participants were asked to report any bright stimuli appearing in their visual field [32, 33, 35–38].

Four out of 10 studies defined PT reporting the percentage or number of trials where subjects report phosphenes [32, 33, 35, 38].

Quantitative synthesis

Phosphen prevalence (Fig. 1)

Results of a study reporting only percentages of phosphen prevalence [37] were not included in the meta-analysis. Despite our intentions, it was impossible to perform an additional individual patient meta-analysis including participants not reporting phosphenes as bearing a 100% threshold, because included studies reported only mean and SD of subjects reporting phosphenes, not reporting rough data for each participant.
### Table 1 Characteristics of included studies

| Study            | Inclusion criteria                                                                 | Exclusion criteria                                      | Diagnosis (no. of subjects, female/male) | Diagnosis, age (years, mean ± SD) | Headache-free interval Before TMS | After TMS | Menstrual phase | Equipment, stimulator, Co/MF/EF/CD | Blinding | Definition of PT | Interslime interval |
|------------------|-----------------------------------------------------------------------------------|----------------------------------------------------------|----------------------------------------|------------------------------------|----------------------------------|-----------|----------------|------------------------------------|-----------|------------------|---------------------|
| A´fra et al. [37] | M: diagnosis according to IHS (14). C: healthy subjects                           | M: drugs altering CNS excitability. C: not reported       | MA (18, –)                             | MA –                              | ≥3 days                          | ≥3 days    | –              | Magstim 200 Ci/2.5/–/130           | –         | –                | –                   |
| Aurora et al. [29]| M: diagnosis according to IHS (14). C: healthy subjects                           | M: drugs altering CNS excitability. C: not reported       | MA (11, 10/1)                          | MA 37 ± 7                         | ≥1 week                          | –         | –              | Cadwell MES 10 C/V2.0/530/95      | Study participants | 20 s              | 20 s                |
| Aurora et al. [30]| M: diagnosis according to IHS (14). C: healthy subjects                           | M: drugs altering CNS excitability. C: not reported       | MA (14, –)                             | M 39.9 ± 8.2                      | ≥1 week                          | –         | –              | Cadwell MES 10 C/V2.0/530/95      | Study participants | 20 s              | 20 s                |
| Mulleners et al. [36] | M: diagnosis according to IHS (14); ≥2 attacks/month in the 3 months before the study. C: no other medical condition; personal or family history of epilepsy | M: contraindication for TMS, any neurologic or ophthalmologic condition other than refractive error; drugs altering CNS excitability. C: lifetime history of ≥2 attacks of migraine and migraines in the past year | MA (16, 14/2)                          | MA –                              | ≥24 h                           | –         | –              | Magstim 200 Ci/2.0/530/30          | Investigators not blinded | ≥5 s              | –                   |
| Bohotin et al. [32] | M: diagnosis according to IHS (14). C: healthy subjects                           | M: no other medical condition; personal or family history of epilepsy | MA (10, –)                             | M 33.5 ± 10.8                     | ≥3 days                          | ≥3 days    | TMS performed 12–16 days after the first day of menses (at mid-cycle) | Magstim Rapid E/1.2/-/70       | –         | Lowest intensity (%) able to evoke PP in at least 3 out of 5 trials | –         |
| Study         | Inclusion criteria                                      | Exclusion criteria                                                                 | Diagnosis (no. of subjects, female/male) | Diagnosis, age (years, mean ± SD) | Headache-free interval | Menstrual phase | Equipment, stimulator, Co/MF/EF/CD | Blinding | Definition of PT | Interstimulus interval |
|--------------|-----------------------------------------------------|-----------------------------------------------------------------------------------|------------------------------------------|-------------------------------------|-----------------------|-----------------|-------------------------------------|----------|----------------|----------------------|
| Aurora et al. [31] | M: diagnosis according to IHS (14). C: healthy subjects | M: >1 muscular contraction headache/month, history of seizures, pacemakers; drugs altering CNS excitability. C: not reported | MA (10, 9/1) MwA (10, 8/2) C (10, 8/2) | MA 38 ± 13 MwA 39 ± 10 C 37 ± 9 | ≥1 week – – | – | Cadwell Magstim Ci/2.0/530/95 | Investigator performing TMS and study participants | Intensity gradually increase until visual experience was reported | 20 s |
| Bohotin et al. [33] | M: diagnosis according to IHS (14). C: healthy subjects | M: neurological, ophthalmological or systemic disorder; personal or family history of epilepsy; prophylactic anti-migraine treatment within the 3 months before the study. C: neurological, ophthalmological or systemic disorder; personal or family history of epilepsy; personal or family history of migraine | MA (13, –) MwA (24, –) C (33, 18/15) | M 30.3 ± 10.1 C 25.5 ± 6.6 | ≥3 days ≥3 days | TMS performed 12–16 days after the first day of menses (at mid-cycle) | Magstim Rapid E/1.2/-/70 | Investigator performing TMS | Lowest intensity (%) able to evoke PP in at least 3 out of 5 trials | – |
| Gerwig et al. [35] | M: diagnosis according to IHS (15) C: healthy subjects | M: acute neurological illness such as epilepsy, organic mental disorder, or alcohol and substance abuse; drugs altering CNS excitability. C: drugs altering CNS excitability; family history of migraine | MA (19, 12/7) MwA (19, 15/4) C (22, 11/11) | MA 32 ± 8 MwA 39 ± 10 C 30 ± 4 | ≥3 days ≥3 days | TMS performed during both menstrual phases | Medtronic Dantec MagPro E/~/-/100 | Investigator performing TMS | Intensity (%) ≥10 s able to evoke PP in at least 5 out of 10 trials | – |
| Gunaydin et al. [34] | M: diagnosis according to IHS (14). C: healthy subjects. | M: drugs altering CNS excitability. C: not reported. | MA (15, 14/1) MwA (15,12/3) C (30, 26/4) | MA 33.9 ± 5.9 MwA 33.0 ± 4.3 C 33.0 ± 4.9 | ≥1 week 3 days | – | Magstim 200 Ci/~/-135 | Investigator performing TMS and study participants | Intensity gradually increase until visual experience was reported | – |
| Khedr et al. [38] | M: diagnosis according to IHS (14). C: healthy subjects. | M: <1 attack of migraine/week; patients taking any drug within 24 h before the study. C: family history of migraine; subjects taking any drug within 24 h before the study | MA (18, –) MwA (10, –) C (20, –) | MA 33.7 ± 6.9 MwA 30.5 ± 7.8 | ≥3 days ≥3 days | Females not tested pre or during menstrual phase | Maglite r 25 E/~/-90 | – | Intensity (%) ≥5 s able to evoke PP in 5 out of 10 trials | – |

C controls, CD outer coil diameter (mm), Ci circular coil, Co coil shape, E figure-of-eight coil, EF electric field strength (V/m), IHS International Headache Society, M migraine patients, MA migraine with aura, MF magnetic field strength (Tesla), MwA migraine without aura, PP phosphenes
Migraine with aura (Fig. 1a)

There were 9 studies with 300 participants. Significant statistical heterogeneity among trials was detected. There was a statistically significant difference in phosphenereporting between migraine with aura and control group, with higher prevalence in migraine group (111/126 vs. 116/174 participants; OR 4.21; 95 % CI 1.18–15.01).

Migraine without aura (Fig. 1b)

There were 8 studies with 274 participants. No significant statistical heterogeneity among trials was detected. There was no statistically significant difference in phosphenereporting between migraine without aura and control group (79/111 vs. 113/163 participants; OR 1.04; 95 % CI 0.58–1.86).

PT values (Fig. 2)

Migraine with aura

Figure-of-eight coil (Fig. 2a) There were 4 studies with 123 participants. Significant statistical heterogeneity among trials was detected. There was no statistically significant difference in phosphenethreshold between migraine with aura and control group (mean difference: 2.05; 95 % CI –12.18 to 16.29).

Circular coil (Fig. 2b) There were 5 studies with 104 participants. Significant statistical heterogeneity among trials was detected. There was a statistically significant difference between groups, with PT being lower in patients with migraine with aura than in controls (mean difference: –28.33; 95 % CI –36.09 to –20.58).

Migraine without aura

Figure-of-eight coil (Fig. 2c) There were 4 studies with 122 participants. Significant statistical heterogeneity among trials was detected. There was no statistically significant difference in phosphenethreshold between migraine without aura and control group (mean difference: 5.52; 95 % CI –8.90 to 19.95).

Circular coil (Fig. 2d) There were 3 studies with 68 participants. No significant statistical heterogeneity among trials was found. There was a statistically significant difference in phosphenethreshold between migraine without aura and control group (mean difference –17.12; 95 % CI –23.81 to –10.43).
In this systematic review, we used systematic and explicit methods to identify, select and critically appraise studies, and to extract data, analyzing them with a meta-analysis. A meta-analysis is the statistical combination of results from two or more separate studies (pair-wise comparisons of interventions), allowing an increase in statistical power, an improvement in precision, sometimes permitting to answer questions not posed by individual studies and to settle controversies arising from conflicting claims.

In the present meta-analysis, we found that patients with migraine with and without aura have a lower PT compared with controls when a circular coil is used; with a figure-of-eight coil the difference is not statistically significant. There was also a statistically significant higher phosphene prevalence in migraine with aura compared with controls. No statistically significant difference was found either in phosphene reporting between patients with migraine without aura and controls, or in PT values obtained by figure-of-eight coil TMS in subjects with migraine with/without aura versus controls. Overall considered (and also taking into account the sample size of each comparison), these results support the hypothesis of a primary visual cortex hyper-excitability in migraine with aura, providing not enough evidence for occipital hyper-excitability in migraine without aura.

### Table 2: PT values.

| Study or Subgroup | Migraine with aura | Controls | Mean Difference | Mean | SD | Total | Year |
|-------------------|--------------------|----------|----------------|------|----|-------|------|
| Bobotim et al. 2002 | 62.8               | 13.39    | 6              | 66.85| 11.93 | 14     | 2002 |
| Bobotim et al. 2003 | 84.25              | 12.52    | 9              | 68.61| 12.49 | 21     | 2003 |
| Gevorgi et al. 2005 | 53.1               | 5.7      | 19             | 64.4 | 10.5  | 22     | 2005 |
| Khadil et al. 2006 | 62.5               | 12.8     | 17             | 72.0 | 10.8  | 15     | 2006 |
| Total (95% CI)   |                    |          |               | 51   | 72   |       |      |

Heterogeneity: Tau² = 189.32; Chi² = 35.08, df = 3 (P < 0.00001); I² = 91%
Test for overall effect: Z = 0.28 (P = 0.78)

![Fig. 2: PT values.](image)

- **a**: Patients with MA versus controls (figure-of-eight coil);
- **b**: patients with MwA versus controls (figure-of-eight coil);
- **c**: patients with MA versus controls (circular coil); and
- **d**: patients with MwA versus controls (circular coil). Total of events in each group was the number of participants reporting phosphenes. Standard deviations in Mulleners et al. [36] were calculated from standard error and number of participants in each group (standard error \( \times \sqrt{\text{number of participants}} \)).
In the evaluation of PT, we also planned to perform an individual patient data meta-analysis including subjects not reporting phosphenes as bearing a 100 % threshold. As a matter of fact, if phosphene prevalence is used as a measure of cortical excitability, then subjects not reporting phosphene should be considered as patients with a 100 % threshold. However, included studies reported mean and SD data obtained only in subjects reporting phosphenes, without reporting rough data for each participant, thus preventing us from performing an analysis based on individual subjects data.

How to consider subjects not experiencing phosphenes at 100 % stimulator intensity is still a matter of debate, since the unresponsiveness to magnetic stimulation may be attributed also to specific anatomical peculiarities.

Indeed in most published studies of PTs, there are a certain number of participants who do not experience phosphenes even at maximum stimulator output. There are some anatomical and methodological reasons which may contribute to explain such a phenomenon [39].

First, it is possible that due to methodological difficulties in mapping PT over each square millimeter of the occipital skull, the correct point of stimulation may not be identified in each subject. Second, unlike primary motor cortex, primary visual cortex (calcarine fissure) is deeply located, lying in mid-sagittal plane, so that magnetic field strength applied over the skull may be insufficient to reach and stimulate the visual cortex. Finally, every millimeter the surface cortex is away from the stimulating coil, approximately an additional 3 % of the maximum power output is required to induce an equivalent level of brain stimulation at the motor cortex (although no similar data on visual cortex stimulation is available in the literature).

Hence, although the unresponsiveness to magnetic stimulation might indicate an extremely low visual cortical excitability (so that subjects not reporting phosphene should be considered as patients with a 100 % threshold), it should be taken into consideration that TMS cannot effectively reach deeply located cortical areas. Phosphen prevalence should therefore be interpreted cautiously: as the unresponsiveness to magnetic stimulation depends not only on cortical excitability levels, but also on anatomical features, phosphene prevalence alone cannot be considered as a measure of cortical excitability, but its evaluation should be integrated with PT values.

**Exploration of heterogeneity**

The results of the present meta-analysis should be read with cautiousness, mainly because of the considerable statistical heterogeneity found in four out of six meta-analytic comparisons, indicative of inconsistency in the results of included studies. The term “statistical heterogeneity” describes the degree of variation in the effect estimates from a set of studies, and indicates the presence of variability among studies beyond the amount expected due solely to the play of chance.

Such a statistical heterogeneity may be explained both by differences in clinical characteristics of study participants (clinical heterogeneity) and by different stimulation procedures (methodological heterogeneity) adopted.

**Clinical heterogeneity**

Regarding clinical heterogeneity, a first aspect to be considered is that, unlike motor TMS, occipital TMS with measuring of PT is a highly subjective procedure, in which different individual attitudes toward detecting, recognizing and reporting phosphenes may play a relevant role. Moreover, the definition of phosphene may be difficult for subjects to understand. Using too detailed definitions or providing too exhaustive instruction may easily introduce biases, and conversely there is the risk that other visual phenomena unrelated to the magnetic stimulus are misinterpreted as phosphenes (risk of false positives). Owing to the subjective nature of phosphenes, a sham stimulation should be added to the standard occipital TMS to reduce the risk of false positives. Sham stimulation may be performed by holding the coil perpendicular to the skull surface resting on the edge; this procedure does not induce a current of sufficient intensity to elicit phosphenes, however, it still provides a comparable acoustic stimulation and sensory percept [40]. This procedure may compensate for the fact that the measurement of phosphenes is subjective by nature, in contrast to the objective measurement of MEPs.

Neuronal excitability of the visual cortex in migraine is not stable but changes relative to the time of the last/next migraine attack [41–44]. Patients should therefore be evaluated in the true interictal period with an adequate headache-free interval (at least 24 h) both before and after the TMS procedure in order to study a homogeneous sample. The variations of cortical excitability might represent the main reason for the data heterogeneity found in the available literature on such a topic. Six out of ten studies in the present review checked and ruled out the occurrence of a migraine attack at least 24 h after TMS recording [32–35, 37, 38]. However, it is worth reporting that even in comparisons between studies performed with an adequate headache-free interval and adopting the same TMS procedures, a significant statistical heterogeneity exists (Fig. 2a, c). This may suggest either that variations of cortical excitability alone do not explain the heterogeneity of studies’ results, or that even among patient studies within the same headache-free interval other factors responsible for clinical heterogeneity exist.
Regarding this last aspect, inter-individual variability in the anatomy of the occipital region and in skull thickness may represent another potentially relevant source of clinical heterogeneity and, to some extent, may be responsible for the impossibility of perceiving phosphenes by some subjects, even when maximum output stimulation is performed [39]. Furthermore, the ovarian cycle may represent another factor influencing cortical excitability [45, 46]; only four studies explicitly assessed such a variable [32, 33, 35, 38], whose effect on cortical excitability is nevertheless still matter of debate [47, 48].

Methodological heterogeneity

Regarding methodological heterogeneity, potentially relevant aspects to be taken into account are the coils’ shape, size and maximum magnetic field strength, and the direction of the current through the stimulating coil (mono- or bi-phasic); these stimulator characteristics are sometimes not explicitly reported in the studies, although they may deeply influence the results. For example, compared with a figure-of-eight coil, a circular coil stimulates a larger cortical area [49, 50], and may generate, at least theoretically, a stronger electric current resulting in a greater probability of evoking phosphenes.

Another potentially relevant source of methodological heterogeneity is due to discrepancies in PT definitions, and, more in general, to the lack of a unique, systematic TMS protocol in the evaluation of PT in migraine.

Especially in comparison, B (phosphen threshold values evaluated by means of figure-of-eight coil) heterogeneity seems to be related to the presence of some outlying studies with results that conflict with the rest of the studies. Repeating pooled analyses on PT values obtained with figure-of-eight coil and excluding one study at a time to vented us from performing a more detailed sensitivity analysis. We did not find any apparent obvious reason (in terms of clinical and/or methodological differences) for the outlying results.

Such a high degree of inconsistency among meta-analysis may be therefore explained not only by clinical or methodological differences among studies, but also by significant variations of cortical excitability among migraine patients. A higher temporal variability among PT measurements over time [21, 22], related to unstable excitability levels in these patients [22, 41–44], might represent the most relevant clinical factor explaining the high inconsistency among study results found in the present review.

Conclusions

In this review, we found that patients with migraine with and without aura have a lower PT compared with controls when a circular coil single-pulse TMS is used; with a figure-of-eight coil the difference is not statistically significant. There was also a statistically significant higher phosphene prevalence in migraine with aura compared with controls. No statistically significant difference was found either in phosphene reporting between patients with migraine without aura and controls, or in PT values obtained by figure-of-eight coil TMS in subjects with migraine with/without aura versus controls.

Overall considered, these results support the hypothesis of a primary visual cortex hyper-excitability in migraine with aura, providing not enough evidence for occipital hyper-excitability in migraine without aura.

A significant statistical heterogeneity reflects the presence of clinical and methodological differences across studies, and higher temporal variabilities among PT measurements over time, related to unstable excitability levels in these patients. A unique, shared protocol for future studies of the PT in migraine patients might overcome such limitations. Patients should be evaluated in the true interictal period with an adequate headache-free interval (at least 24 h) both before and after the TMS procedure in order to study a homogeneous sample. Furthermore, skull thickness and ovarian cycle should be assessed as possible confounding variables, and sham stimulation should be performed to reduce the rate of false positives. Since the unresponsiveness to magnetic stimulation depends on cortical excitability levels and on anatomical peculiarities, phosphene prevalence alone cannot be considered as an appropriate measure of cortical excitability, but should be integrated with the parameter of PT. Further studies conducted with a systematic TMS protocol are required to confirm whether and to what extent PT values are reduced in migraine.

Acknowledgments We are in debt with Dr. Stefano Zago (Department of Neurological Sciences, University of Milan, Italy), who kindly provided us information on a still unpublished work (Cappellari et al.). We also thank Dr. Sheena Aurora for providing us useful additional information on her works. This systematic review received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Conflict of interest The authors declare that there is no conflict of interest.

Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.
Appendix: search strategies used in the review

MEDLINE

("Migraine Disorders"[Mesh] OR migraine* OR migraine) AND ("Phosphenes"[Mesh] OR phosphene* OR "phosphen threshold") AND "Transcranial Magnetic Stimulation"[Mesh]): 78 results.

EMBASE

(migrain* AND phosphen* AND “Transcranial Magnetic Stimulation”): 31 results.

References

1. Welch KMA, DAndrea G, Tepley N, Barkley G, Ramadan NM (1990) The concept of migraine as a state of central neuronal hyperexcitability. Neurolog Clin 8:817–828
2. Welch KM, Barkeley GL, Tepley N, Ramadan NM (1993) Central neurogenic mechanisms of migraine. Neurology 43(Suppl 3):S21–S25
3. Shepherd AJ (2001) Increased visual after-effects following pattern adaptation in migraine: a lack of intracortical excitation? Brain 124:2310–2318
4. Lehtonen JB (1974) Visual evoked cortical potentials for single flashes and flickering light in migraine. Headache 14:1–12
5. Connolly JF, Gawel M, Rose FC (1982) Migraine patients exhibit abnormalities in the visual evoked potential. J Neurol Neurosurg Psychiatry 45:464–467
6. Diener HC, Scholz E, Dichgans J et al (1989) Central effects of drugs used in migraine prophylaxis evaluated by visual evoked potentials. Ann Neurol 25:125–130
7. Amassian VE, Cracco RQ, Maccabee PJ, Rudell A, Eberie L (1989) Suppression of visual perception by magnetic coil stimulation of human occipital cortex. Electroencephal Clin Neurophysiol 74:458–462
8. Meyer BU, Diehl R, Steinmetz H, Britton TC, Benecke R (1991) Magnetic stimuli applied over motor and visual cortex: influence of coil position and field polarity on motor response, phosphenes and eye movements. Electroencephal Clin Neurophysiol Suppl 43:121–134
9. Höffken O, Stude P, Lenz M, Bach M, Dinse HR, Tegenthoff M (2009) Visual paired-pulse stimulation reveals enhanced visual cortex excitability in migraineurs. Eur J Neurosci 30:714–720
10. Merabet LB, Theoret H, Pasqual-Leone A (2003) Transcranial magnetic stimulation as an investigative tool in the study of visual function. Optom Vis Sci 80:356–368
11. Ambrosini A, Schoenen J (2003) The electrophysiology of migraine. Curr Opin Neurol 16:327–331
12. Schoenen J, Ambrosini A, Sándor PS, Maertens de Noordhout A (2003) Evoked potentials and transcranial magnetic stimulation in migraine: published data and viewpoint on their pathophysiologic significance. Clin Neurophysiol 114:955–972
13. Fumal A, Bohotin V, Vandenheede M, Schoenen J (2003) Transcranial magnetic stimulation in migraine: a review of facts and controversies. Acta Neurol Belg 103:144–154
14. Schoenen J (2006) Neurophysiological features of the migrainous brain. Neurursci 27(Suppl 2):S77–S81
15. Coppola G, Pierelli F, Schoenen J (2007) Is the cerebral cortex hyperexcitable or hyperresponsive in migraine? Cephalalgia 27:1427–1439
16. International Headache Society (1988) Classification and diagnostic criteria for headache disorders, cranial neuralgia and facial pain. Cephalalgia 8(Suppl 7):1–96
17. Headache Classification Subcommittee of the International Headache Society (2004) The International Classification of Headaches, 2nd edn. Cephalalgia 24 Suppl 1:9–160
18. Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327:557–560
19. Brighina F, Piazza A, Daniele O, Fierro B (2002) Modulation of visual cortical excitability in migraine with aura: effects of 1 Hz repetitive transcranial magnetic stimulation. Exp Brain Res 145:177–181
20. Battelli L, Black KR, Wray SH (2002) Transcranial magnetic stimulation of visual area V5 in migraine. Neurology 58:1066–1069
21. Young WB, Oshinsky ML, Shechter AL, Gebeline-Myers C, Bradley KC, Wassermann EM (2004) Consecutive transcranial magnetic stimulation: phosphene thresholds in migraineurs and controls. Headache 44:131–135
22. Antal A, Arlt S, Nitsche MA, Chaadaie Z, Paulaus W (2006) Higher variability of phosphene thresholds in migraineurs than in controls: a consecutive transcranial magnetic stimulation study. Cephalalgia 26:865–870
23. Aurora SK, Barrodale P, Chronicle EP, Mulleners WM (2005) Cortical inhibition is reduced in chronic and episodic migraine and demonstrates a spectrum of illness. Headache 45:546–552
24. Cappellari A, Zago S, Valli G, Ferrucci R, De Benedittis G (2011) Metagnetophosphenes in migraineurs: failure to find a cortical hyper- or hypoexcitability by single-pulse transcranial magnetic stimulation. Unpublished (as supplied June 2011)
25. Aguggia M, Zibetti M, Febbraro A, Mutani R (1999) Transcranial magnetic stimulation in migraine with aura: further evidence of occipital cortex hyperexcitability. Cephalalgia 19:465
26. Aurora SK, Al-Sayed F, Welch KM (1999) The threshold for magnetophosphenes is lower in migraine. Neurology 52:A472
27. Valli G, Cappellari A, Zago S, Ciammola A, De Benedittis G (2001) Is migraine associated with hyperexcitability of the occipital cortex? A transcranial magnetic stimulation controlled study. Neurology 56:A142
28. Valli G, Cappellari A, Zago S, Ciammola A, De Benedittis G (2002) Migraine is not associated with hyperexcitability of the occipital cortex. A transcranial magnetic stimulation controlled study. In: Proceedings of the 10th World Congress of Pain 2002. IASP Press, Seattle
29. Aurora SK, Ahmad BK, Welch KM, Bhardhwaj P, Ramadan NM (1998) Transcranial magnetic stimulation confirms hyperexcitability of occipital cortex in migraine. Neurology 50:1111–1114
30. Aurora SK, Cao Y, Bowyer SM, Welch KM (1999) The occipital cortex is hyperexcitable in migraine: experimental evidence. Headache 39:469–476
31. Aurora SK, Welch KM, Al-Sayed F (2003) The threshold for phosphenes is lower in migraine. Cephalalgia 23:258–263
32. Bohotin V, Fumal A, Vandenheede M, Gérard P et al (2002) Effects of repetitive transcranial magnetic stimulation on visual evoked potentials in migraine. Brain 125:912–922
33. Bohotin V, Fumal A, Vandenheede B, Bohotin C, Schoenen J (2003) Excitability of visual V1-V2 and motor cortices to single transcranial magnetic stimuli in migraine: a reappraisal using a figure-of-eight coil. Cephalalgia 23:264–270
34. Gunaydin S, Soysal A, Atay T, Arpaci B (2006) Motor and occipital cortex excitability in migraine patients. Can J Neurol Sci 33:63–67
35. Gerwig M, Niehaus L, Kastrup O, Stude P, Diener HC (2005) Visual cortex excitability in migraine evaluated by single and paired magnetic stimuli. Headache 45:1394–1399
36. Mulleners WM, Chronicle EP, Palmer JE, Koehler PJ, Vredeveld JW (2001) Visual cortex excitability in migraine with and without aura. Headache 41:565–572
37. Áfra J, Mascia A, Gérard P, Maertens de Noordhout A, Schoenen J (1998) Interictal cortical excitability in migraine: a study using transcranial magnetic stimulation of motor and visual cortices. Ann Neurol 44:209–215
38. Khedr EM, Ahmed MA, Mohamed KA (2006) Motor and visual cortical excitability in migraineurs with or without aura: transcranial magnetic stimulation. Neurophysiol Clin 36:13–18
39. Brigo F (2012) Occipital TMS in dementia with Lewy bodies: how to consider subjects not reporting phosphenes? Br J Psychiatry (in press)
40. Sparing R, Mottaghy FM, Ganis G, Thompson WL, Töpper R, Kosslyn SM, Pascual-Leone A (2002) Visual cortex excitability increases during visual mental imagery—a TMS study in healthy human subjects. Brain Res 938(1–2):92–97
41. Kropp P, Gerber WD (1998) Prediction of migraine attacks using a slow cortical potential, the contingent negative variation. Neurosci Lett 257:73–76
42. Evers S, Quibeldey F, Grottemeyer KH, Suhr B, Husstedt IW (1999) Dynamic changes of cognitive habituation and serotonin metabolism during the migraine interval. Cephalalgia 19:485–491
43. Áfra J, Sandor PS, Schoenen J (2000) Habituation of visual and intensity dependence of auditory evoked cortical potentials tend to normalize just before and during the migraine attack. Cephalalgia 20:714–719
44. Siniatchkin M, Reich AL, Shepherd AJ, van Baalen A, Siebner HR, Stephani U (2009) Peri-ictal changes of cortical excitability in children suffering from migraine without aura. Pain 15:132–140
45. Smith MJ, Keel JC, Greenberg BD, Adams LF, Schmidt PJ, Rubinow DA, Wassermann EM (1999) Menstrual cycle effects on cortical excitability. Neurology 53:2069–2072
46. Smith MJ, Adams LF, Schmidt PJ, Rubinow DR, Wassermann EM (2002) Effects of ovarian hormones on human cortical excitability. Ann Neurol 51:599–603
47. Young WB, Oshinsky ML, Shechter AL, Wassermann EM (2001) Consecutive transcranial magnetic stimulation induced phosphen thresholds in migraineurs and controls. Neurology 56:A142
48. Boros K, Poreisz C, Paulus W, Antal A (2009) Does the menstrual cycle influence the motor and phosphen thresholds in migraine? Eur J Neuro 16:367–374
49. Cohen LG, Roth BJ, Nilsson J, Dang N, Panizza M, Bandinelli S, Friau W, Hallett M (1990) Effects of coil design on delivery of focal magnetic stimulation. Technical considerations. Electroencephalogr Clin Neurophysiol 75:350–357
50. Hallett M (2000) Transcranial magnetic stimulation and the human brain. Nature 406:147–150